Cabazitaxel for hormone-relapsed metastatic prostate cancer previously treated with a docetaxel-containing regimen (review of TA255)

Kearns, B; Pandor, A; Stevenson, M; Sanderson, J; Chambers, D; Clowes, M; Kumar, M.S and Graham, J, Benjamin Kearns, Abdullah Pandor, Matt Stevenson, Jean Sanderson, Duncan Chambers, Mark Clowes, Satish Kumar, John Graham

    Research output: Book/Report › Commissioned report

    731 Downloads (Pure)

    Abstract

    Prostate cancer is the most common cancer amongst men in the England and currently affects ~40,000 people around 6,000 of whom suffer from metastatic disease. Overall patients with metastatic disease have a life expectancy of less than 24 months and a poor prognosis.

    Docetaxel was the first agent to show survival benefit in metastatic Hormone Refractory Prostate Cancer (mHRPC) and since approval by NICE in 2006 (TA101) has for many years been the mainstay of treatment.

    To appraise the clinical and cost effectiveness of cabazitaxel within its marketing authorisation for treating hormone-relapsed metastatic prostate cancer previously treated with a docetaxel-containing regimen.
    Original languageEnglish
    Place of PublicationNational Institute for Health and Care Excellence
    PublisherNational Institute for Health and Care Excellence
    Number of pages36
    Publication statusPublished - 01 Jun 2016

    Access to Document

      Fingerprint Dive into the research topics of 'Cabazitaxel for hormone-relapsed metastatic prostate cancer previously treated with a docetaxel-containing regimen (review of TA255)'. Together they form a unique fingerprint.

      Cite this